Cantor Fitzgerald Expects Lower Earnings for Elevance Health

Elevance Health, Inc. (NYSE:ELVFree Report) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings estimates for shares of Elevance Health in a research report issued on Wednesday, April 23rd. Cantor Fitzgerald analyst S. James now forecasts that the company will post earnings per share of $34.47 for the year, down from their previous forecast of $34.57. Cantor Fitzgerald has a “Overweight” rating and a $485.00 price target on the stock. The consensus estimate for Elevance Health’s current full-year earnings is $33.96 per share.

Elevance Health (NYSE:ELVGet Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The company reported $11.97 earnings per share for the quarter, topping the consensus estimate of $10.60 by $1.37. The business had revenue of $48.77 billion during the quarter, compared to analysts’ expectations of $46.26 billion. Elevance Health had a return on equity of 18.28% and a net margin of 3.38%.

A number of other brokerages have also issued reports on ELV. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Elevance Health in a research report on Friday, March 28th. Barclays increased their target price on shares of Elevance Health from $512.00 to $522.00 and gave the company an “overweight” rating in a research note on Wednesday. StockNews.com upgraded Elevance Health from a “hold” rating to a “buy” rating in a research note on Thursday, March 20th. Argus upgraded Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 price objective for the company in a research report on Monday, March 17th. Finally, Truist Financial lifted their price objective on Elevance Health from $480.00 to $510.00 and gave the stock a “buy” rating in a report on Friday, April 11th. Four research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $509.44.

View Our Latest Stock Analysis on ELV

Elevance Health Stock Up 0.5 %

Shares of ELV stock opened at $429.08 on Thursday. Elevance Health has a 12 month low of $362.21 and a 12 month high of $567.26. The company has a quick ratio of 1.50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71. The firm has a market cap of $97.14 billion, a PE ratio of 16.75, a price-to-earnings-growth ratio of 1.18 and a beta of 0.77. The stock has a 50 day moving average of $419.22 and a 200-day moving average of $408.94.

Institutional Trading of Elevance Health

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Elevance Health in the 3rd quarter valued at $2,828,000. Te Ahumairangi Investment Management Ltd increased its position in Elevance Health by 39.6% in the third quarter. Te Ahumairangi Investment Management Ltd now owns 10,508 shares of the company’s stock worth $5,433,000 after purchasing an additional 2,983 shares during the period. Tudor Financial Inc. bought a new stake in Elevance Health during the 3rd quarter worth about $235,000. Anchor Investment Management LLC lifted its position in Elevance Health by 22.9% during the 3rd quarter. Anchor Investment Management LLC now owns 6,098 shares of the company’s stock valued at $3,171,000 after purchasing an additional 1,135 shares during the period. Finally, World Investment Advisors LLC bought a new position in shares of Elevance Health in the 3rd quarter valued at about $8,855,000. 89.24% of the stock is owned by institutional investors.

Insider Buying and Selling at Elevance Health

In related news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the company’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $396.30, for a total transaction of $1,388,635.20. Following the transaction, the executive vice president now owns 10,116 shares in the company, valued at $4,008,970.80. This represents a 25.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $415.13, for a total transaction of $183,902.59. Following the completion of the sale, the chief accounting officer now owns 1,847 shares of the company’s stock, valued at $766,745.11. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.29% of the company’s stock.

Elevance Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Tuesday, June 10th will be issued a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.59%. The ex-dividend date is Tuesday, June 10th. Elevance Health’s dividend payout ratio is currently 26.71%.

Elevance Health Company Profile

(Get Free Report)

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

See Also

Earnings History and Estimates for Elevance Health (NYSE:ELV)

Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.